Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nigel Courtenay-Luck"'
Autor:
Daniel J. Fernandes, Nigel Courtenay-Luck, Eleanor K. Spicer, Weiwei Chen, Sridharan Soundararajan
Supplementary Figure 2 from The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2e492c0e9488edd1a4d5544ad2be5a
https://doi.org/10.1158/0008-5472.22371132
https://doi.org/10.1158/0008-5472.22371132
Autor:
Daniel J. Fernandes, Nigel Courtenay-Luck, Eleanor K. Spicer, Weiwei Chen, Sridharan Soundararajan
We sought to determine whether nucleolin, a bcl-2 mRNA-binding protein, has a role in the regulation of bcl-2 mRNA stability in MCF-7 and MDA-MB-231 breast cancer cells. Furthermore, we examined the efficacy of the aptamer AS1411 in targeting nucleol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25937b31ab2603e4693a4d6fd5c4fa0b
https://doi.org/10.1158/0008-5472.c.6496677
https://doi.org/10.1158/0008-5472.c.6496677
Autor:
Daniel J. Fernandes, Nigel Courtenay-Luck, Eleanor K. Spicer, Weiwei Chen, Sridharan Soundararajan
Supplementary Figure 1 from The Nucleolin Targeting Aptamer AS1411 Destabilizes Bcl-2 Messenger RNA in Human Breast Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71e8099718eb97a7e479203741bf9fbf
https://doi.org/10.1158/0008-5472.22371135
https://doi.org/10.1158/0008-5472.22371135
Autor:
Tomoya Ohno, Claire V. Hutchinson, John Sharpe, Guillaume Cartron, Gilles Salles, Simon Rule, Franck Morschhauser, Hideyuki Honda, Bruno Cazin, Virginia Jamieson, Shin-ichiro Abe, Lionel Karlin, Toshio Yoshizawa, Harriet S. Walter, Akihisa Nishimura, Philippe Quittet, Martin J. S. Dyer, Kevin J. Duffy, Nimish Shah, Joseph Birkett, Ceri Jones, Christopher Fegan, Nigel Courtenay-Luck
Publikováno v:
Blood
Blood, American Society of Hematology, 2016, 127 (4), pp.411-419. ⟨10.1182/blood-2015-08-664086⟩
Blood, American Society of Hematology, 2016, 127 (4), pp.411-419. ⟨10.1182/blood-2015-08-664086⟩
We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9 dose-escalation cohorts ranging from 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b534430b52404c7057a10be3c08f0895
https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796198
https://hal-univ-lyon1.archives-ouvertes.fr/hal-01796198
Autor:
Nigel Courtenay-Luck, Sridharan Soundararajan, Li Wang, Weiwei Chen, David R. Jones, Eleanor K. Spicer, Vijayalakshmi Sridharan, Daniel J. Fernandes
Publikováno v:
Molecular Pharmacology. 76:984-991
AS1411 is a DNA aptamer that is in phase II clinical trials for relapsed or refractory acute myeloid leukemia and for renal cell carcinoma. AS1411 binds to nucleolin, a protein that is overexpressed in the cytoplasm and on the plasma membrane of some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7ce13279b0805d295733bf7a392d2ca
https://doi.org/10.1124/mol.109.055947
https://doi.org/10.1124/mol.109.055947
Autor:
Franziska Schaedli Stark, Nigel Courtenay Luck, Jyotsna Fuloria, Virginia F. Borges, Charles L. Shapiro, Mark D. Pegram, Nuhad K. Ibrahim, Karen Wang, Susan Perez
Publikováno v:
Breast Cancer Research : BCR
Introduction MUC1 is a cell-surface glycoprotein that establishes a molecular barrier at the epithelial surface and engages in morphogenetic signal transduction. Alterations in MUC1 glycosylation accompany the development of cancer and influence cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3152f7374ec4966ed713ebb68004d4b
https://pubmed.ncbi.nlm.nih.gov/19811637
https://pubmed.ncbi.nlm.nih.gov/19811637
Autor:
Tomoko Yasuhiro, Martin J. S. Dyer, Simon Rule, Lionel Karlin, Toshio Yoshizawa, Kevin J. Duffy, Guillaume Cartron, Claire V. Hutchinson, Louis Terriou, Christopher Fegan, Nimish Shah, Gilles Salles, John Sharpe, Akhisa Nishimura, Nigel Courtenay-Luck, Joanne Bagshawe, Joseph Birkett, Shin-ichiro Abe, Hideyuki Honda, Franck Morschhauser, Harriet S. Walter
Publikováno v:
ResearcherID
Introduction Bruton’s tyrosine kinase (BTK) is a critical kinase involved in B-cell receptor signal transduction. ONO-4059, a highly potent and selective oral BTK inhibitor has demonstrated anti-tumour activity in pre-clinical models (Yasuhiro et a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01451c8b2682e6d7ddf718a3904721f6
https://doi.org/10.1182/blood.v124.21.3328.3328
https://doi.org/10.1182/blood.v124.21.3328.3328
Autor:
Mark Pegram, Nigel Courtenay-Luck
Publikováno v:
Clinical Immunology. 123:S110-S111
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc640efbbc323cb017e85e6446deef04
https://doi.org/10.1016/j.clim.2007.03.494
https://doi.org/10.1016/j.clim.2007.03.494
Publikováno v:
Bioscience Reports. 2:589-595
Quiescent 3T3 cells resting in the G O phase of the cell cycle can be stimulated to reinitiate DNA synthesis by combinations of chemically diverse agents which act synergistically when added to cultures maintained in serum-free medium. Understanding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da2e02da6e490f420d2364a51781e3dd
https://doi.org/10.1007/bf01314220
https://doi.org/10.1007/bf01314220